ABSTRACT
Background: This study was planned to evaluate all the cases of ? thalassaemia major, already receiving one of the oral iron chelators for a comparison among the efficacy, safety and economy of deferasirox and deferiprone to establish the better option in an Indian scenario.Methods: We identified two groups of patients: 38 treated with deferasirox and 35 treated with deferiprone. Laboratory parameters such as serum ferritin, creatinine, SGPT, Hb, CBC and urine were recorded at the time of inclusion and at 1, 3 and 6 months after the inclusion. The primary outcome variable was serum Ferritin level at the start and at the end of study. Serum ferritin level was carried out by microparticle enzyme linked immunoassay.Results: Before the study, the mean hemoglobin level was 7.32±1.50mg/dL ranged from 4 to 10.8 in deferasirox group and 7.54±1.15mg/dL ranged from 5.5 to 8.8 in deferiprone group. At the time of inclusion, study population was characterized by a mean serum ferritin value of 4735.11±450.01 SE in deferasirox and 4315.97±340.75 SE in deferiprone group. After one month the mean serum ferritin increases to 4578.66±371.96 in deferasirox and 4388.82±316.16 in deferiprone group. After three month the mean serum ferritin reduces to 4295.60±377.37 in deferasirox and 3988.88±349.84 in Deferiprone group.Conclusions: Thus, we conclude that deferasirox and deferiprone are well tolerated, have few adverse effects and almost have a comparable effect in lowering of the patient's serum ferritin level. Deferiprone is more cost effective but needs a strict control on compliance owing to requirement in three divided doses per day.
ABSTRACT
Background: Haemoglobinopathies like thalassaemia and sickle cell anaemia etc are increasing due to unawareness of rural population. This study indicates type of haemoglobinopathies amongst the patients of a rural based tertiary care hospital in one year and nine months. Methods: Five hundred ten patients were studied during last one year and nine month for all suspected cases of haemolytic anaemia based on Complete Blood Count, Red cell indices and Peripheral blood smear examination. Sickling test, test for Hb F and haemoglobin electrophoresis with quantification of bands are done in all these cases Results: Out of all 510 cases of anaemia 461 cases (90.39%) were confirmed to nonhaemolytic anaemia whereas 49 cases (9.60%) had shown abnormal haemoglobin bands on electrophoresis. Out of these 49 cases 29 (59.18%) were Males and 20 (40.81%) were females. Most common Haemoglobinopathy observed was Sickle cell Thalassaemia 23 (4.50%) followed by Thalassaemia Trait 9 (1.76%), Sickle Cell trait 7 (1.37%). Thalassaemia Major 5 (0.98%) & Sickle Cell Disease 5 (0.98%) have equal prevalence. The onset of disease was most prominent in Neonatal to pediatric age group including early adolescent (0-18 years) followed by reproductive age group (19- 45 years). Few cases of old age (46+ years) were detected. Conclusion: Study provides data on the spectrum & pattern of Haemoglobinopathies in a rural tertiary care centre. Screening of all anemic patients should be done for Haemoglobinopathy and proper Genetic counseling must be given to all cases to prevent incidence of cases in future generation.